Establishment Labs (NASDAQ:ESTA) Price Target Raised to $70.00 at BTIG Research

Establishment Labs (NASDAQ:ESTA) had its target price hoisted by BTIG Research from $62.00 to $70.00 in a research note issued to investors on Wednesday morning, MarketBeat.com reports. BTIG Research currently has a buy rating on the stock.

A number of other equities research analysts have also weighed in on the stock. Mizuho boosted their target price on shares of Establishment Labs from $58.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday, July 16th. Wall Street Zen raised shares of Establishment Labs from a “sell” rating to a “hold” rating in a research note on Sunday, October 19th. Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a research report on Tuesday, October 7th. Canaccord Genuity Group assumed coverage on shares of Establishment Labs in a research report on Wednesday, August 20th. They set a “buy” rating and a $60.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Establishment Labs in a research report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $57.83.

Establishment Labs Price Performance

ESTA stock opened at $60.51 on Wednesday. The firm has a market cap of $1.75 billion, a P/E ratio of -19.84 and a beta of 0.98. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 9.71. The company’s 50-day moving average price is $43.18 and its two-hundred day moving average price is $39.99. Establishment Labs has a 12 month low of $26.56 and a 12 month high of $62.25.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.16. The company had revenue of $53.78 million for the quarter, compared to analyst estimates of $52.28 million. Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The firm’s revenue was up 33.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.59) EPS. Establishment Labs has set its FY 2025 guidance at EPS. On average, analysts anticipate that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Institutional Trading of Establishment Labs

Several institutional investors have recently made changes to their positions in ESTA. State of Wyoming bought a new stake in shares of Establishment Labs in the 3rd quarter worth $71,000. ANTIPODES PARTNERS Ltd bought a new position in Establishment Labs during the first quarter valued at about $81,000. Osaic Holdings Inc. lifted its holdings in Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after purchasing an additional 1,800 shares during the last quarter. CWM LLC lifted its holdings in Establishment Labs by 45.9% during the second quarter. CWM LLC now owns 2,182 shares of the company’s stock valued at $93,000 after purchasing an additional 686 shares during the last quarter. Finally, Brian Low Financial Group LLC purchased a new stake in Establishment Labs during the third quarter valued at about $223,000. Institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.